Zealand Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide-based products that target indications of significant unmet clinical need and commercial potential. The company has a proven track record in bringing compounds fast and efficiently through early clinical development. Subsequently we strive to enter into joint-research and/or commercial partnerships. Since 1999, Zealand's scientists have built a pipeline of proprietary programs where seven compounds entered development. Our current development portfolio consists of one Phase III program, one Phase II program, three Phase I programs and various late stage lead development programs. The company is commercially validated through its agreements with Sanofi-Aventis (ZP10), Wyeth (ZP1609) Action Pharma (ZP1480) and Helsinn Healthcare (ZP1846).

In addition Zealand has a number of early stage drug discovery and pre-clinical programs in the disease areas: Obesity, Diabetes, Cardiac Arrhythmias, Acute Kidney Injury and Osteoporosis.

Zealand Pharma is based in Copenhagen and has 65 employees.

Web: www.zealandpharma.com